Physician profile
Michael Broker
NPI 1619473196
$1,508.51
in general payments reported to CMS, 2019-2025
14 companies · $214 in 2025
The $214 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.00 · 2022: $202 · 2023: $509 · 2024: $569 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $928 · Education: $363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $928.39 |
| Education | $363.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $474.22 | 2022-2024 | Farxiga, Brilinta, Atacand |
| Abbott Laboratories | $298.41 | 2023 | Ensite |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $234.18 | 2024-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $158.23 | 2024-2025 | Amvuttra |
| E.R. Squibb & Sons, L.L.C. | $63.55 | 2022-2025 | Eliquis, Camzyos |
| Pfizer INC. | $59.16 | 2021-2024 | |
| Irhythm Technologies, INC. | $48.55 | 2023 | Zio Xt Patch |
| Abiomed | $31.68 | 2024 | Impella |
| Csl Behring | $30.57 | 2024 | Kcentra |
| Amgen INC. | $26.50 | 2024 | |
| Kestra Medical Technology Services, INC. | $23.46 | 2024 | Assure Wcd |
| Kiniksa Pharmaceuticals International, Plc | $22.92 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $22.44 | 2024 | Xarelto |
| Nxstage Medical, INC. | $14.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Broker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.